HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
DistillerSR Launches Smart Chat, an AI Chat Interface Built Into Its Evidence Platform27.10.2026 15:55:00 CET | Press release
OTTAWA, ON / ACCESS Newswire / October 27, 2026 / DistillerSR® Inc., the pioneer and market leader in AI-enabled literature review automation and evidence management, today announced the launch of Smart Chat. Smart Chat brings DistillerSR's Agentic AI capabilities in-platform. Since September 2025, DistillerSR Agentic AI has eliminated evidence silos at customer organizations by connecting Large Language Models to a repository of expertly validated literature evidence. Smart Chat now makes that same capability available natively within DistillerSR's secure platform. "While researchers recognize the power of generative AI, many life sciences organizations cannot risk connecting external LLMs to their sensitive research data," said Peter O'Blenis, CEO of DistillerSR. "Smart Chat removes that barrier. It is built directly into the platform teams already use, works exclusively with their own DistillerSR projects, and is included with every version of DistillerSR." Smart Chat works only wit
PuK Gaming Launches First Officially Licensed Fortnite Mobile Accessories Range27.10.2026 14:15:00 CET | Press release
LONDON, UK / ACCESS Newswire / October 27, 2026 / PuK Gaming LTD, the UK-based designer of premium mobile gaming accessories, today launched Drop 1 of its officially licensed Fortnite range, in a deal facilitated by Epic Games' licensing agency IMG Licensing. The five-product range offers console-grade control to how millions play Fortnite: on a phone. The PuK Thumbstick, PuK Triggers, PuK Link Cable and PuK Thumb Sleeves attach in seconds, no battery charge or pairing required; the whole ecosystem fits in your pocket. The Hot Drop Bundle includes three of the four products, plus a collector tin and zip case. Every Drop 1 product includes a code for a bonus in-game item, with the Thumbstick granting the Stage Dive Glider and the Hot Drop Bundle granting the Battle Call Emote. "Fortnite defines competitive play for mobile gamers," said Scotty Tidwell, CEO of PuK Gaming. "Drop 1 gives Fortnite players more ways to play on mobile with console-grade low-latency control and precision." PuK
QorusDocs Launches QPilot Workspace, Where People and AI Agents Build Winning Proposals Together27.10.2026 14:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / October 27, 2026 / QorusDocs, the pursuit intelligence platform for professional services, legal, technology services and architecture, engineering and construction (AEC) firms, today launched QPilot Workspace, a shared space where business development teams and AI agents complete every pursuit together, from the moment an opportunity opens to the signed contract. QPilot Workspace is guided by pursuit intelligence that grounds every proposal, pitch and RFP response in a firm's real people, projects and pursuit history. Service firms are fielding more RFPs than ever, according to QorusDocs' research. More than two-thirds (68%) saw proposal volume climb last year, with most having to decline participation in 10 to 19% of the RFPs they receive. "We're responding to more RFPs than ever with shorter turnaround times," said Heather Almquist, senior vice president at Marsh, a leading professional services firm. "One of the hardest parts is pulling together the
Formerra Adjusts Transportation Surcharge Amid Continued Freight and Logistics Pressures27.10.2026 14:00:00 CET | Press release
ROMEOVILLE, IL / ACCESS Newswire / October 27, 2026 / Formerra, a leader in performance materials distribution, announced an increase to its transportation surcharge to address continued cost escalation in the freight and logistics market. Beginning November 2, 2026, a surcharge of $450 per delivery will apply to all shipments across North, Central, and South America. Costs in the freight and logistics market have increased steadily as the industry navigates higher operating costs, tighter capacity, and a shortage of qualified drivers. At the same time, diesel prices reached an all-time high in September. "Freight costs across the Americas remain elevated, and we do not expect these pressures to ease in the near term," said Tom Kelly, Formerra CEO. "The adjustment helps offset market pressures beyond our control while enabling us to maintain the dependable service our customers count on from Formerra." Customers should contact their Formerra representative for more information. About F
Camino and Nittetsu Launch Next Phase of Detailed Engineering for the Puquios Copper Project in Chile with Ausenco27.10.2026 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 27, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that following the successful completion of the Critical Engineering Phase study with Ausenco, the company officially held the kickoff meeting to launch the next phase of detailed engineering services with Ausenco Chile Ltda. ("Ausenco") for the Puquios copper project (the "Puquios Project"). This transition into detailed engineering represents a major step forward in advancing the project, locking in technical specifications, and preparing the Puquios Project for the construction phase. Marcelo Bruna, CEO of the Puquios Joint Venture said, "With the commencement of detailed engineering, the executive team remains focused on strict milestone tracking and cost control as we progress towards breaking ground." Jay Chmelauskas, CEO of Camino further commented, "We are working closely with Nittetsu to finalize agreements to source a pote
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom